Dr. Ralph F. Cox JR., M.D.
Family Medicine (Family Medicine Physician)
- Medicare participating
At a glance
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 355
Licensed in Texas since 1983, according to the Texas Medical Board. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Family Medicine Physician primary
TX license G3253 (first issued 1983; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Medicare patients and services
- Medicare patients, 2024
- 355
- Services billed
- 7,604
- Patients’ average age
- 69
| Service | Times | Patients |
|---|---|---|
| Chronic care management services, first 20 minutes of clinical staff time directed by health care professional, per calendar month | 408 | 173 |
| Established patient office or other outpatient visit, 30-39 minutes | 395 | 135 |
| Established patient office or other outpatient visit, 20-29 minutes | 348 | 120 |
| Management using the results of remote vital sign monitoring per calendar month, each additional 20 minutes | 282 | 48 |
| Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | 209 | 47 |
| Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | 207 | 48 |
| Chronic care management services for two or more chronic conditions, additional 20 minutes of clinical staff time directed by health care professional, per calendar month | 194 | 129 |
| Telephone medical discussion provided by nonphysician professional, 21-30 minutes | 110 | 60 |
| Advance care planning, first 30 minutes | 96 | 92 |
| Annual depression screening, 5 to 15 minutes | 91 | 91 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Buprenorphine-Naloxone (buprenorphine hcl/naloxone hcl) Other prescribers in Dallas, TX | 111 |
| Shingrix (varicella-zoster ge/as01b/pf) Other prescribers in Dallas, TX | 105 |
| Atorvastatin Calcium Other prescribers in Dallas, TX | 83 |
| Amlodipine Besylate Other prescribers in Dallas, TX | 63 |
| Abrysvo (rsv vacc, pref a and pref b/pf) Other prescribers in Dallas, TX | 61 |
| Lisinopril Other prescribers in Dallas, TX | 56 |
| Rosuvastatin Calcium Other prescribers in Dallas, TX | 56 |
| Hydrocodone-Acetaminophen (hydrocodone/acetaminophen) Other prescribers in Dallas, TX | 55 |
| Levothyroxine Sodium Other prescribers in Dallas, TX | 44 |
| Losartan Potassium Other prescribers in Dallas, TX | 43 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $139 in total to this clinician.
| Otsuka America Pharmaceutical, Inc. | $70.62 |
|---|---|
| Abbott Laboratories | $19.71 |
| Novo Nordisk Inc | $17.41 |
| AstraZeneca Pharmaceuticals LP | $15.68 |
| Exact Sciences Corporation | $15.63 |
| Food and Beverage | $139 |
|---|
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 3 companies. The companies reported $822,257 in research payments for these studies, mostly to the institutions running them.
- A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ≥18 Years of Age for the Prevention of Acute Gastroenteritis
ModernaTX, Inc. · Active, not recruiting · NCT06592794 - A Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an Adjuvanted Influenza Vaccine Compared to a Non-adjuvanted Influenza Vaccine in Adults ≥65 Years of Age
Seqirus USA Inc · Completed · NCT06087640 - A Study to Evaluate the Efficacy, Safety, and Immunogenicity of mRNA-1647 Cytomegalovirus (CMV) Vaccine in Healthy Participants 16 to 40 Years of Age
ModernaTX, Inc. · Terminated · NCT05085366 - A Phase 1/2 Study to Evaluate ALN-KHK in Overweight to Obese Healthy Volunteers and Obese Patients With T2DM
Alnylam Pharmaceuticals Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.